Inavolisib
Sign in to save this workspacePrimary targets: PI3K · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.679
CATDS
0.022
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Inavolisib. Strongest target: DNA_PK at 24.2% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | DNA_PK | 24.2% | 75.8% |
| 2 | LRRK2 | 21.6% | 78.4% |
| 3 | WNK3 | 20.9% | 79.1% |
| 4 | IKKE_IKBKE | 17.9% | 82.1% |
| 5 | SGK2 | 16.2% | 83.8% |
| 6 | ERK1 | 14.3% | 85.7% |
| 7 | PLK3 | 13.2% | 86.8% |
| 8 | PAK5 | 12.2% | 87.8% |
| 9 | MLK3_MAP3K11 | 12.1% | 87.9% |
| 10 | CDK9_CYCLIN_K | 12.0% | 88.0% |
| 11 | RIPK4 | 12.0% | 88.0% |
| 12 | P38G | 11.7% | 88.3% |
| 13 | MST4 | 11.6% | 88.4% |
| 14 | P38D_MAPK13 | 11.6% | 88.4% |
| 15 | PDK2_PDHK2 | 11.5% | 88.5% |
| 16 | ALK2_ACVR1 | 11.1% | 88.9% |
| 17 | ERK5_MAPK7 | 10.7% | 89.3% |
| 18 | CAMK1A | 10.7% | 89.3% |
| 19 | CAMKK1 | 10.4% | 89.6% |
| 20 | CDK4_CYCLIN_D3 | 10.4% | 89.6% |
Selectivity landscape
Where Inavolisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Inavolisib.
Atlas insights for Inavolisib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 167.04 | |
| ALLOGRAFT_REJECTION | 556.30 | |
| ANDROGEN_RESPONSE | 172.46 | |
| ANGIOGENESIS | 120.67 | |
| APICAL_JUNCTION | 580.50 | |
| APICAL_SURFACE | 107.01 | |
| APOPTOSIS | 651.99 | |
| BILE_ACID_METABOLISM | 57.83 | |
| CHOLESTEROL_HOMEOSTASIS | 82.82 | |
| COAGULATION | 104.98 | |
| COMPLEMENT | 340.32 | |
| DNA_REPAIR | 146.07 | |
| E2F_TARGETS | 462.55 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 143.86 | |
| ESTROGEN_RESPONSE_EARLY | 300.13 | |
| ESTROGEN_RESPONSE_LATE | 271.52 | |
| FATTY_ACID_METABOLISM | 36.23 | |
| G2M_CHECKPOINT | 427.60 | |
| GLYCOLYSIS | 188.10 | |
| HEDGEHOG_SIGNALING | 47.45 | |
| HEME_METABOLISM | 217.37 | |
| HYPOXIA | 418.26 | |
| IL2_STAT5_SIGNALING | 266.22 | |
| IL6_JAK_STAT3_SIGNALING | 266.72 | |
| INFLAMMATORY_RESPONSE | 346.78 | |
| INTERFERON_ALPHA_RESPONSE | 60.85 | |
| INTERFERON_GAMMA_RESPONSE | 380.12 | |
| KRAS_SIGNALING_DN | 113.49 | |
| KRAS_SIGNALING_UP | 154.18 | |
| MITOTIC_SPINDLE | 477.04 | |
| MTORC1_SIGNALING | 333.40 | |
| MYC_TARGETS_V1 | 331.19 | |
| MYC_TARGETS_V2 | 103.23 | |
| MYOGENESIS | 274.38 | |
| NOTCH_SIGNALING | 17.07 | |
| OXIDATIVE_PHOSPHORYLATION | 93.02 | |
| P53_PATHWAY | 407.65 | |
| PANCREAS_BETA_CELLS | 47.90 | |
| PEROXISOME | 90.10 | |
| PI3K_AKT_MTOR_SIGNALING | 692.47 | |
| PROTEIN_SECRETION | 170.14 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 37.59 | |
| SPERMATOGENESIS | 119.93 | |
| TGF_BETA_SIGNALING | 133.12 | |
| TNFA_SIGNALING_VIA_NFKB | 313.13 | |
| UNFOLDED_PROTEIN_RESPONSE | 152.90 | |
| UV_RESPONSE_DN | 317.61 | |
| UV_RESPONSE_UP | 305.41 | |
| WNT_BETA_CATENIN_SIGNALING | 181.38 | |
| XENOBIOTIC_METABOLISM | 150.86 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.858 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.832 |
| SRR23303752 | — | 0.831 |
| C3N-03420 | — | 0.827 |
| SRR12202498 | — | 0.826 |
Annotations
Sign in to read and post annotations.
Loading…